Syntax Bio
About Syntax Bio
Syntax Bio is a therapeutics startup. Syntax Bio's investor base includes 13 institutional funds, with its lead investor leading the most recent equity round.
Syntax Bio is a Chicago-based synthetic biology company that uses its proprietary Cellgorithm platform — a CRISPR-based system — to program and accelerate stem cell differentiation into specific therapeutic cell types. The company is advancing pancreatic beta cell therapy for type 1 diabetes and developing scalable regenerative medicines. Syntax Bio emerged from the University of Illinois Chicago and has raised over $25 million in total funding.
Investors in Syntax Bio
13 institutional investors
Co-investors
Questions about Syntax Bio
How much has Syntax Bio raised?
Syntax Bio has raised null across undefined funding rounds since undefined.
Who are the investors of Syntax Bio?
Syntax Bio's investors include Astellas Venture Management, Illumina Ventures, DCVC Bio, Civilization Ventures, EGB Capital, Mansueto Office, Portal Innovations, Draper Associates, Allegis Capital, LongGame, Mayo Clinic, Illinois Ventures, Walder Ventures.